genedrive plc (GDR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, genedrive plc (GDR) has a cash flow conversion efficiency ratio of -1.421x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-2.04 Million ≈ $-248.70 USD) by net assets (GBX1.44 Million ≈ $174.96 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see genedrive plc (GDR) market capitalisation for the company's overall valuation and market capitalisation.
genedrive plc - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how genedrive plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
genedrive plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of genedrive plc ranked by their cash flow conversion efficiency. Explore GDR cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CleanTech Lithium plc
LSE:CTL
|
-0.037x |
|
Orchard Funding Group PLC
LSE:ORCH
|
-0.043x |
|
Shearwater Group plc
LSE:SWG
|
-0.070x |
|
Tavistock Investments Plc
LSE:TAVI
|
-0.096x |
|
Cambridge Cognition Holdings Plc
LSE:COG
|
-0.196x |
|
I.Ceram SA
PA:ALICR
|
0.094x |
|
Lexington Gold Ltd
LSE:LEX
|
-0.028x |
|
Virgin Wines UK PLC
LSE:VINO
|
-0.137x |
Annual Cash Flow Conversion Efficiency for genedrive plc (2006–2025)
The table below shows the annual cash flow conversion efficiency of genedrive plc from 2006 to 2025. View today's stock price for genedrive plc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | GBX1.44 Million ≈ $174.96 |
GBX-5.10 Million ≈ $-620.64 |
-3.547x | -404.51% |
| 2024-06-30 | GBX5.36 Million ≈ $652.04 |
GBX-3.77 Million ≈ $-458.46 |
-0.703x | +62.00% |
| 2023-06-30 | GBX2.04 Million ≈ $248.33 |
GBX-3.78 Million ≈ $-459.43 |
-1.850x | -125.18% |
| 2022-06-30 | GBX5.61 Million ≈ $682.70 |
GBX-4.61 Million ≈ $-560.90 |
-0.822x | +43.07% |
| 2021-06-30 | GBX3.59 Million ≈ $437.04 |
GBX-5.18 Million ≈ $-630.74 |
-1.443x | -227.33% |
| 2020-06-30 | GBX-3.34 Million ≈ $-406.62 |
GBX-3.79 Million ≈ $-460.89 |
1.133x | -22.43% |
| 2019-06-30 | GBX-2.48 Million ≈ $-301.50 |
GBX-3.62 Million ≈ $-440.57 |
1.461x | +39.82% |
| 2018-06-30 | GBX-2.44 Million ≈ $-296.51 |
GBX-2.55 Million ≈ $-309.90 |
1.045x | +295.77% |
| 2017-06-30 | GBX3.44 Million ≈ $418.67 |
GBX-1.84 Million ≈ $-223.51 |
-0.534x | +42.77% |
| 2016-06-30 | GBX3.75 Million ≈ $456.63 |
GBX-3.50 Million ≈ $-425.97 |
-0.933x | -169.33% |
| 2015-06-30 | GBX9.54 Million ≈ $1.16K |
GBX-3.31 Million ≈ $-402.24 |
-0.346x | -244.58% |
| 2014-06-30 | GBX10.86 Million ≈ $1.32K |
GBX-1.09 Million ≈ $-132.86 |
-0.101x | -97.99% |
| 2013-06-30 | GBX12.05 Million ≈ $1.47K |
GBX-612.00K ≈ $-74.46 |
-0.051x | -66.01% |
| 2012-06-30 | GBX8.86 Million ≈ $1.08K |
GBX-271.00K ≈ $-32.97 |
-0.031x | +72.95% |
| 2011-06-30 | GBX6.18 Million ≈ $752.17 |
GBX-699.00K ≈ $-85.05 |
-0.113x | +8.53% |
| 2010-06-30 | GBX5.78 Million ≈ $703.75 |
GBX-715.00K ≈ $-86.99 |
-0.124x | -118.01% |
| 2009-06-30 | GBX2.76 Million ≈ $335.81 |
GBX1.89 Million ≈ $230.45 |
0.686x | +256.66% |
| 2008-06-30 | GBX2.58 Million ≈ $314.15 |
GBX-1.13 Million ≈ $-137.61 |
-0.438x | -41.49% |
| 2007-06-30 | GBX2.60 Million ≈ $315.98 |
GBX-804.00K ≈ $-97.82 |
-0.310x | +61.17% |
| 2006-06-30 | GBX1.09 Million ≈ $133.23 |
GBX-873.00K ≈ $-106.22 |
-0.797x | -- |
About genedrive plc
genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides Genedrive system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnos… Read more